Holen Sie sich die Stockscreener-App
25.30
11.55%
2.61
Schlusskurs vom Vortag:
$22.69
Offen:
$23.95
24-Stunden-Volumen:
3.18M
Relative Volume:
1.05
Marktkapitalisierung:
$1.58B
Einnahmen:
$14.34M
Nettoeinkommen (Verlust:
$-199.00M
KGV:
-6.4541
EPS:
-3.92
Netto-Cashflow:
$-183.51M
1W Leistung:
+10.81%
1M Leistung:
+4.67%
6M Leistung:
+64.56%
1J Leistung:
+59.89%
1-Tages-Spanne:
$23.71
$25.80
1-Wochen-Bereich:
$21.64
$25.80
52-Wochen-Spanne:
$7.76
$71.50
Uniqure N V Stock (QURE) Company Profile
Firmenname
Uniqure N V
Sektor
Branche
Telefon
1-339-970-7000
Adresse
PAASHEUVELWEG 25A, AMSTERDAM
Vergleichen Sie QURE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
25.33 | 1.41B | 14.34M | -199.00M | -183.51M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.28 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
751.47 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
818.35 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.26 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
341.10 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-04 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-08-14 | Hochstufung | Mizuho | Neutral → Outperform |
| 2025-04-01 | Fortgesetzt | Chardan Capital Markets | Buy |
| 2024-12-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-02-29 | Herabstufung | Goldman | Buy → Neutral |
| 2023-12-19 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-03-17 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-05-21 | Eingeleitet | UBS | Neutral |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-01 | Hochstufung | Mizuho | Neutral → Buy |
| 2021-01-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-11-11 | Eingeleitet | Berenberg | Buy |
| 2020-11-09 | Eingeleitet | Jefferies | Buy |
| 2020-11-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-08-25 | Eingeleitet | Raymond James | Strong Buy |
| 2020-07-31 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-06-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | Eingeleitet | Cowen | Outperform |
| 2019-12-03 | Eingeleitet | Goldman | Buy |
| 2019-11-05 | Eingeleitet | Credit Suisse | Outperform |
| 2019-10-11 | Eingeleitet | Stifel | Buy |
| 2019-09-25 | Eingeleitet | Bernstein | Outperform |
| 2019-09-12 | Eingeleitet | Mizuho | Buy |
| 2019-07-30 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-07-08 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2019-04-12 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-03-29 | Eingeleitet | Robert W. Baird | Outperform |
Alle ansehen
Uniqure N V Aktie (QURE) Neueste Nachrichten
uniQure (NASDAQ:QURE) Shares Gap UpStill a Buy? - MarketBeat
uniQure N.V. $QURE Shares Sold by SG Americas Securities LLC - MarketBeat
Huntington's Disease Market Poised for Transformation Through - openPR.com
UNIQURE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
H.C. Wainwright Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $70 - 富途资讯
QURE INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving uniQURE N.V. - ACCESS Newswire
Here’s Why uniQure (QURE) Fell in Q3 - Insider Monkey
uniQure N.V. (NASDAQ:QURE) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Notice of QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - PR Newswire
Short Interest in uniQure N.V. (NASDAQ:QURE) Rises By 33.8% - MarketBeat
(QURE) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
QURE Investigation Reminder: Kessler Topaz Meltzer & - GlobeNewswire
QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - GlobeNewswire Inc.
uniQure (NASDAQ:QURE) Shares Up 5%Here's What Happened - MarketBeat
uniQure (QURE) Surges 17.9% Ahead of 2 Health Conferences - MSN
Setup Watch: Is AMPGW subject to activist investor interestEarnings Risk Report & Growth Focused Stock Pick Reports - baoquankhu1.vn
Downgrade Watch: Will uniQure NV stock benefit from M ALong Setup & Daily Market Momentum Tracking - baoquankhu1.vn
Robert Gut Sells 25,613 Shares of uniQure (NASDAQ:QURE) Stock - MarketBeat
RSI Check: Can uniQure NV continue delivering strong returnsJuly 2025 Snapshot & AI Powered Market Entry Ideas - baoquankhu1.vn
Health Check: How Prudently Does UniQure (NASDAQ:QURE) Use Debt? - 富途牛牛
uniQure stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com Nigeria
Cantor Fitzgerald Maintains UniQure NV(QURE.US) With Buy Rating, Cuts Target Price to $55 - 富途资讯
uniQure stock rating reiterated at Overweight by Cantor Fitzgerald By Investing.com - Investing.com Australia
uniQure stock falls after FDA feedback on gene therapy application - MSN
Ideas Watch: Does uniQure NV stock trade at a discount to peersJuly 2025 Outlook & Daily Chart Pattern Signal Reports - moha.gov.vn
How Investors Are Reacting To uniQure (QURE) After Its Pivotal FDA Type A Meeting On AMT-130 - Yahoo Finance
Assessing uniQure (QURE) Valuation After Recent Volatility And Gene Therapy Progress - Yahoo Finance
uniQure updates gene therapy pipeline and regulatory outlook - TipRanks
uniQure N.V. Updates on Gene Therapy Developments - TradingView — Track All Markets
uniQure (NASDAQ:QURE) Director Sells $174,319.20 in Stock - MarketBeat
uniQure (NASDAQ:QURE) Shares Down 9.2%Should You Sell? - MarketBeat
QURE Investigation Reminder: Kessler Topaz Meltzer & Check, - GlobeNewswire
Is UniQure (QURE) One of the Promising Stocks to Buy Under $50? - Insider Monkey
uniQure Shares Skyrocket After Positive Huntington’s Disease Gene Therapy Data - MSN
uniQure (NASDAQ:QURE) Rating Lowered to Sell at Wall Street Zen - MarketBeat
uniQure N.V. Investigation Notice: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - NewMediaWire
uniQure N.V. Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - NewMediaWire
uniQure schedules FDA meeting to discuss accelerated approval for HD therapy - Investing.com Nigeria
uniQure (QURE) Surges on FDA Meeting for Gene Therapy Approval - GuruFocus
UniQure Announces FDA Type A Meeting To Discuss BLA Data For Huntington's Gene Therapy - Nasdaq
uniQure stock soars after FDA meeting scheduled on Huntington’s therapy - Investing.com
US-listed shares of uniQure rise 13% premarket as FDA review talks revive hopes for Huntington's therapy - marketscreener.com
uniQure's (QURE) Gene Therapy for Huntington's Disease Advances with FDA Meeting - GuruFocus
uniQure gains as FDA sets up meeting on gene therapy (QURE:NASDAQ) - Seeking Alpha
uniQure stock soars after FDA meeting scheduled on Huntington’s therapy By Investing.com - Investing.com South Africa
uniQure prepares for FDA Type A meeting on AMT-130 - TipRanks
uniQure schedules FDA meeting to discuss accelerated approval for HD therapy By Investing.com - Investing.com South Africa
uniQure Announces Type A Meeting Scheduled with FDA - The Manila Times
uniQure N.V. Schedules FDA Meeting for AMT-130 Approval - TradingView — Track All Markets
QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourage - GuruFocus
QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - primepublishers.com
Finanzdaten der Uniqure N V-Aktie (QURE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Uniqure N V-Aktie (QURE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Gut Robert | Director |
Jan 12 '26 |
Sale |
24.62 |
25,613 |
630,483 |
32,342 |
| Kaye Jack | Director |
Jan 09 '26 |
Option Exercise |
19.39 |
6,390 |
123,902 |
26,829 |
| Kaye Jack | Director |
Jan 09 '26 |
Sale |
27.28 |
6,390 |
174,319 |
20,439 |
2.77%
2.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):